New Hope for Severe Depression Through Vagus Nerve Stimulation

Depression impacts over 300 million people globally, and while treatment can often help, finding the right medication or therapy can be a process of trial and error. Once effective, such treatments can significantly improve daily life. However, for around a third of individuals suffering from depression, standard treatments simply don’t work.

The challenge isn’t solely about the complexities of treating depression; sometimes, even effective treatments can cease to provide relief. Yet, recent outcomes from a significant clinical trial indicate that a small implanted device may offer lasting relief to those dealing with severe treatment-resistant depression.

“We’ve witnessed patients improving and sustaining that improvement,” mentions psychiatry researcher Charles Conway from Washington University in St. Louis.

This treatment, known as vagus nerve stimulation (VNS), has shown promise. In a study published in the International Journal of Neuropsychopharmacology, Conway and others noted that VNS led to sustained enhancements for some individuals who had endured severe depression for many years—sometimes even decades.

The vagus nerve, which is one of the body’s longest nerves, connects the brain to various organs, including the heart and lungs. VNS therapy works by surgically implanting a small device—similar to a pacemaker—under the skin of the chest. A wire connects this device to the left vagus nerve in the neck, delivering gentle electrical pulses at set intervals.

The research was part of the RECOVER trial that included 493 participants in the US, all of whom had experienced at least four failed attempts at treatment for their current depressive episode. In fact, many had tried more than that. As Conway shared, patients had, on average, previously attempted 13 different treatments that didn’t work before joining the trial.

Half of the participants received active VNS right away, while the other half served as a control group with their devices switched off for the first year. Last year’s reports showed that those who received VNS demonstrated encouraging improvements in their depressive symptoms.

The findings from 2026 focused on 214 patients who started with active VNS. Researchers aimed to evaluate if the positive changes were maintained into the second year.

The results were largely affirmative. “Even a partial response to treatment can be life-changing,” Conway points out. After 12 months, about 69 percent of participants noted a significant improvement, with over 80 percent sustaining or enhancing those improvements after 24 months, impacting their quality of life and daily functioning.

Interestingly, of those who felt the most benefit at the 12-month mark—defined as a 50 percent or more reduction in symptoms—92 percent still reported positive effects two years later. “We were surprised to find that one in five patients experienced no depressive symptoms by the end of two years,” Conway mentioned, highlighting the unusual nature of such results compared to other studies on treatment-resistant depression.

On average, trial participants had lived with depression for 29 years, with three-quarters unable to work. “We believe this trial represents one of the most severely affected groups of treatment-resistant patients ever studied,” Conway stated.

One particularly interesting aspect was that about one-third of participants who saw no significant benefits in the first year improved by the second year, implying that VNS might take more time to show its effects for some individuals.

It’s essential to note that the trial was funded by LivaNova, the maker of the VNS device, which does have a vested interest in the outcome. The data are expected to guide coverage decisions by the US Centers for Medicare and Medicaid Services, which presently do not provide coverage for this therapy.

While VNS received FDA approval in 2005 for treatment-resistant depression, its mechanisms are still not completely understood.

At present, VNS is not a quick fix, and responses can vary between individuals. This gradual onset makes the study’s long-term results particularly noteworthy. “Seeing such outcomes in this complex illness gives me hope for the future of this treatment,” Conway concluded.

The research has been published in the International Journal of Neuropsychopharmacology.